Enhancement of gemcitabine toxicity and specificity through PI3K/Akt/Nrf2 pathway inhibition in pancreatic cancer
BD B10 was identified as a non-toxic drug sensitiser that enhanced gemcitabine efficacy in PDAC cells and improved the therapeutic index by inhibiting key survival and resistance pathways. Specific roles for BD B10 in PDAC were identified and further testing may prove drug sensitisers have a more general application to enhance drug therapies.
Authors
- Philip J. Day (ORCID: https://orcid.org/0000-0003-0130-4797)
- Stephen O’Hagan
- Yu-Shan Chen
Institutions
- University of Cape Town (ZA)
- University of Manchester (GB)
- Biology of Infection (FR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-02-16
- DOI
- https://doi.org/10.3389/fphar.2026.1724989
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council